These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 37041225

  • 1. CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
    Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M.
    Cancer Immunol Immunother; 2023 Jul; 72(7):2499-2512. PubMed ID: 37041225
    [Abstract] [Full Text] [Related]

  • 2. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.
    Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
    [Abstract] [Full Text] [Related]

  • 3. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
    Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB.
    Blood Cancer J; 2015 Aug 21; 5(8):e340. PubMed ID: 26295610
    [Abstract] [Full Text] [Related]

  • 4. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
    Blood; 2018 Dec 06; 132(23):2484-2494. PubMed ID: 30275109
    [Abstract] [Full Text] [Related]

  • 5. [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells].
    Zhang T, Chen ML, Liu XY, He HZ, Xu YX, Tian Z, Xing HY, Tang KJ, Rao Q, Wang M, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2022 May 14; 43(5):376-382. PubMed ID: 35680594
    [Abstract] [Full Text] [Related]

  • 6. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
    Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB.
    Blood; 2014 Jan 23; 123(4):554-61. PubMed ID: 24311721
    [Abstract] [Full Text] [Related]

  • 7. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R, Saul D, Braun M, Tohumeken S, Völkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D.
    J Immunother Cancer; 2018 Nov 05; 6(1):116. PubMed ID: 30396365
    [Abstract] [Full Text] [Related]

  • 8. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B.
    Mol Cancer Ther; 2014 Jun 05; 13(6):1549-57. PubMed ID: 24674885
    [Abstract] [Full Text] [Related]

  • 9. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
    Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.
    Blood; 2014 Jan 16; 123(3):356-65. PubMed ID: 24300852
    [Abstract] [Full Text] [Related]

  • 10. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T.
    Oncotarget; 2016 Nov 22; 7(47):76902-76919. PubMed ID: 27708227
    [Abstract] [Full Text] [Related]

  • 11. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A, Krause SW.
    Leukemia; 2013 Apr 22; 27(5):1107-15. PubMed ID: 23178753
    [Abstract] [Full Text] [Related]

  • 12. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
    Zugmaier G, Klinger M, Schmidt M, Subklewe M.
    Mol Immunol; 2015 Oct 22; 67(2 Pt A):58-66. PubMed ID: 25883042
    [Abstract] [Full Text] [Related]

  • 13. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
    Deisting W, Raum T, Kufer P, Baeuerle PA, Münz M.
    PLoS One; 2015 Oct 22; 10(10):e0141669. PubMed ID: 26510188
    [Abstract] [Full Text] [Related]

  • 14. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
    Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, Kischel R, Chen G, Walter RB.
    PLoS One; 2015 Oct 22; 10(8):e0135945. PubMed ID: 26305211
    [Abstract] [Full Text] [Related]

  • 15. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N.
    Adv Exp Med Biol; 2017 Oct 22; 995():73-95. PubMed ID: 28321813
    [Abstract] [Full Text] [Related]

  • 16. A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia.
    Burke A, Borot F, Du X, Churchill M, Ding J, Grass AM, DeSouza P, Ali AM, Mukherjee S.
    Oncogene; 2023 Jan 22; 42(1):26-34. PubMed ID: 36357573
    [Abstract] [Full Text] [Related]

  • 17. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.
    PLoS One; 2016 Jan 22; 11(12):e0166891. PubMed ID: 27907031
    [Abstract] [Full Text] [Related]

  • 18. Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
    Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li CM, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T.
    Mol Cancer Ther; 2020 Sep 22; 19(9):1875-1888. PubMed ID: 32518207
    [Abstract] [Full Text] [Related]

  • 19. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S.
    Proc Natl Acad Sci U S A; 2021 Jul 27; 118(30):. PubMed ID: 34301886
    [Abstract] [Full Text] [Related]

  • 20. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, Guenot J, Walter RB.
    Clin Cancer Res; 2016 Dec 01; 22(23):5829-5838. PubMed ID: 27189165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.